stoxline Quote Chart Rank Option Currency Glossary
  
Checkmate Pharmaceuticals, Inc. (CMPI)
10.5  0 (0%)    12-31 19:00
Open: 10.49
High: 10.5
Volume: 63,651
  
Pre. Close: 10.5
Low: 10.49
Market Cap: 0(M)
Technical analysis
2022-11-18 4:19:32 PM
Short term     
Mid term     
Targets 6-month :  12.26 1-year :  14.32
Resists First :  10.5 Second :  12.26
Pivot price 10.5
Supports First :  10.49 Second :  10.48
MAs MA(5) :  10.5 MA(20) :  10.5
MA(100) :  10.5 MA(250) :  7.51
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  100 D(3) :  100
RSI RSI(14): 88.8
52-week High :  10.5 Low :  2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CMPI ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.51 - 10.56 10.56 - 10.6
Low: 10.37 - 10.43 10.43 - 10.48
Close: 10.41 - 10.5 10.5 - 10.58
Company Description

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Headline News

Thu, 12 May 2022
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update - Yahoo Finance

Tue, 19 Apr 2022
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in ... - Yahoo Finance

Mon, 20 Dec 2021
Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D. - GlobeNewswire

Wed, 27 Oct 2021
Checkmate Pharmaceuticals Appoints Alan Fuhrman as Interim CEO - citybiz

Mon, 10 May 2021
Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP ... - GlobeNewswire

Tue, 22 Dec 2020
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 22 (M)
Shares Float 7 (M)
Held by Insiders 4.6 (%)
Held by Institutions 77.5 (%)
Shares Short 79 (K)
Shares Short P.Month 42 (K)
Stock Financials
EPS -2.93
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.53
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -42.4 %
Return on Equity (ttm) -75.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -50 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -3.6
PEG Ratio -0.1
Price to Book value 4.13
Price to Sales 0
Price to Cash Flow -4.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android